NLS Pharmaceutics AG (NLSP)
| Previous Close | 0.7384 |
| Open | 0.7550 |
| Bid | 0.7171 x 900 |
| Ask | 0.7250 x 1100 |
| Day's Range | 0.7102 - 0.7550 |
| 52 Week Range | 0.4200 - 1.8800 |
| Volume | |
| Avg. Volume | 130,564 |
| Market Cap | 23.255M |
| Beta (5Y Monthly) | -0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.75 |
ACCESSWIRENLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:
- ACCESSWIRE
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has reviewed the full protocol for the NLS-1031 study, part of the Phase 3 program for Mazindol ER, called AMAZE.
- ACCESSWIRE
NLS Pharmaceutics Releases the Results from its Annual General Meeting
NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the NLS Shareholders approved all of the Board of Directors' proposals for the 2023 Annual General Meeting (AGM) that took place in Zürich, Switzerland today.
